RxDoctor Payments DataLook up a doctor →

Jeffrey Carstens, MD

Cardiovascular Disease · Omaha, NENPI 1730265976

Payments from drug & device makers

$299,336in general payments, 2019–2025

Across 558 payments — averaging $536.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$157K
  • Edwards Lifesciences$29K
  • Lilly USA, LLC$27K
  • Amarin Pharma, Inc.$23K
  • Medtronic$21K
  • Boehringer Ingelheim$19K
  • plus $22K from 25 others

What the payments were for

  • Consulting fees$38,26531%
  • Speaking & faculty fees$33,57027%
  • Travel & lodging$29,01323%
  • Food & beverage$23,25019%
  • Education$1080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$299,336 in reported general payments places this provider in the 95th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$21,676
Medicare patients
246
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$28,010
XareltoRivaroxaban15$12,406
JardianceEmpagliflozin14$9,083
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$392
Metoprolol Succinate37$363
Atorvastatin Calcium41$258
Amlodipine Besylate32$247
Rosuvastatin Calcium14$175
Carvedilol18$111
Nitroglycerin13$109
ClopidogrelClopidogrel Bisulfate11$86
Spironolactone20$75
Metoprolol Tartrate11$66
Furosemide43$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$359$28,01026 claims
Johnson & JohnsonXarelto$424$12,40615 claims
Boehringer IngelheimJardiance$19,192$9,08314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →